Abstract
Dyslipidemia is the category of diseases that are known for many years and treated more groups of lipid-lowering drugs. Despite the large amount of products available, there are patients who do not achieve satisfactory results with previously known and standard treatment or intolerant.
This text presents a summary of current potential new drugs in pharmacotherapy dyslipidemia. Included are both completely new, hypothetical possibilities destinations and are given drugs found in advanced stages of clinical research, which is likely to be soon put into practice.